Home | Publications | Healthcare place holder
place holder place holder

Healthcare

Autoimmune Market Outlook to 2012


Publication Date   August 2007
Publisher   Business Insights
Product Type  
Pages   216
ISBN Number   not applicable
Product Code   RBI145
Ask a question about this product?

Price £1,495.00

approximately: $2,961 | €1,900

Summary


Autoimmune related disorders continue to maintain prominence within the global disease burden, having achieved a worldwide market growth of 9.4% over the 2002-06 period. However, the inherent threat of generic competition and novel product launches are forecast to transform the dynamics of the autoimmune market over the next 5 years. The autoimmune pipeline represents a key opportunity for drug development companies, with the potential for success largely attributable to substantial unmet demand, a significant patient population and the medical proclivity for long term treatments. In consequence, the effective exploitation of market potential is becoming increasingly crucial, and hinges upon drug developments that accurately reflect the shifting demographics of autoimmune disorders and unmet patient needs. Autoimmune Market Outlook to 2012 is a new report published by Business Insights, examining how the competitive dynamics of major pharma companies will influence the market positions of products and shape the direction of future global autoimmunology. Market trends and leading brands of treatment are extensively profiled, while the most commercially promising R&D therapies are investigated and assessed to discover their sales potential. This report will also provide a comprehensive epidemiological analysis of the major indications and detailed product sales forecasts. Use this report to identify opportunities in the autoimmune pipeline, assess the dynamics of leading competitors and evaluate the impact of key trends across the global market.

Content


  • Executive Summary
    • Patient potential
    • Global market analysis
    • Pipeline analysis
    • Competitive landscape
  • Chapter 1 Epidemiology of the autoimmune
    • therapeutic area
  • Summary
    • Introduction
    • Osteoarthritis and rheumatoid arthritis
  • Overview
    • Diagnosis, treatment and management
    • Epidemiology
    • Forecast epidemiology
    • Spondyloarthropathies
  • Overview
    • Diagnosis, treatment and management
    • Epidemiology
    • Forecast epidemiology
    • Lupus
  • Overview
    • Diagnosis, treatment and management
    • Epidemiology
    • Forecast epidemiology
    • Psoriasis
  • Overview
    • Diagnosis, treatment and management
    • Epidemiology
    • Forecast epidemiology
    • Crohn's disease
  • Overview
    • Diagnosis, treatment and management
    • Epidemiology
    • Forecast epidemiology
  • Chapter 2 Global market analysis
  • Summary
    • Introduction
    • Market analysis by country
    • Licensing/generics trends
    • Market analysis by drug class
    • Leading brands dynamics
    • Key events in the autoimmune market
    • Immunosuppressants
    • Competitive dynamics of immunosuppressants
    • Leading brands of immunosuppressants
    • Key brands analysis
    • Immunosuppressants sales forecasts to 2012
    • Antirheumatic agents
    • Competitive dynamics of antirheumatic agents
    • Leading brands of antirheumatic agents
    • Key brands analysis
    • Antirheumatic sales forecasts to 2012
    • NSAIDs
    • Competitive dynamics of NSAIDs
    • Leading brands of NSAIDs
    • Key brands analysis
    • NSAIDs sales forecasts to 2012
    • Topical antirheumatics
    • Competitive dynamics of topical antirheumatics
    • Leading brands of topical antirheumatics
    • Topical antirheumatic sales forecasts to 2012
    • COX-II inhibitors
    • Competitive dynamics of COX-II inhibitors
    • Leading brands of COX-II inhibitors
    • Key brands analysis
    • COX-II inhibitors sales forecasts to 2012
    • Corticosteroids
    • Competitive dynamics of corticosteroids
    • Leading brands of corticosteroids
    • Corticosteroids sales forecasts to 2012
    • Total autoimmune sales forecasts to 2012
  • Chapter 3 Pipeline analysis
  • Summary
    • Introduction
    • Key trends in R&D
    • Biologics
    • Combination drugs
    • Fully human monoclonal antibodies
    • B-cell depleting therapies
    • The autoimmune pipeline
    • Leading drugs in development
    • Profiles of key pipeline products
    • Phase III compounds
    • Licofelone (ML3000)
    • Cimzia (certolizumab pegol)
    • LymphoStat-B (belimumab)
    • Golimumab (CNTO 148)
    • R1594 / PRO70769 (ocrelizumab)
    • Recently marketed drugs
    • Actemra (tocilizumab)
    • Rituxan (rituximab)
    • Taclonex (calcipotriene/betamethasone)
    • Panaclar/BG-12
    • Pipeline forecasts
    • Factors affecting forecasts
    • Autoimmune pipeline forecasts
  • Chapter 4 Competitive landscape
    • Summary
      • Introduction
      • Amgen
    • Overview
      • Sales focus by drug class
      • Marketed product portfolio
      • R&D pipeline analysis
      • Strategic and growth analysis
      • Drivers of growth
      • Resistors of growth
      • Johnson & Johnson
    • Overview
      • Sales focus by drug class
      • Marketed product portfolio
      • R&D pipeline analysis
      • Strategic and growth analysis
      • Drivers of growth
      • Resistors of growth
      • Pfizer
    • Overview
      • Sales focus by drug class
      • Marketed product portfolio
      • R&D pipeline analysis
      • Strategic and growth analysis
      • Drivers of growth
      • Resistors of growth
      • Novartis
    • Overview
      • Sales focus by drug class
      • Marketed product portfolio
      • R&D pipeline analysis
      • Strategic and growth analysis
      • Drivers of growth
      • Resistors of growth
      • Abbott
    • Overview
      • Sales focus by drug class
      • Marketed product portfolio
      • R&D pipeline analysis
      • Strategic and growth analysis
      • Drivers of growth
      • Resistors of growth
      • Wyeth
    • Overview
      • Sales focus by drug class
      • Marketed product portfolio
      • R&D pipeline analysis
      • Strategic and growth analysis
      • Drivers of growth
      • Resistors of growth
      • Roche
    • Overview
      • Sales focus by drug class
      • Marketed product portfolio
      • R&D pipeline analysis
      • Strategic and growth analysis
      • Drivers of growth
      • Resistors of growth
      • Astellas
    • Overview
      • Sales focus by drug class
      • Marketed product portfolio
      • R&D pipeline analysis
      • Strategic and growth analysis
      • Drivers of growth
      • Resistors of growth
      • Boehringer Ingleheim
    • Overview
      • Sales focus by drug class
      • Marketed product portfolio
      • R&D pipeline analysis
      • Strategic and growth analysis
      • Drivers of growth
      • Resistors of growth
      • Schering-Plough
    • Overview
      • Sales focus by drug class
      • Marketed product portfolio
      • R&D pipeline analysis
      • Strategic and growth analysis
      • Drivers of growth
      • Resistors of growth
  • Chapter 5 Appendix
    • IMS data
    • L4A0 Immunosuppressive agents
    • M1A1 Antirheumatics, non-steroidal plain
    • M1A2 Antirheumatics, non-steroidal combination
    • M1A3 Coxibs
    • M1B0 Antirheumatics, steroidal combination
    • M1C0 Specific anti-rheumatic agents
    • M2A0 Antirheumatics, topical
    • Index
  • List of Figures
    • Figure 1.1: Typical treatment patterns in the treatment of psoriasis
    • Figure 2.2: Global autoimmune market share by geography, 2006
    • Figure 2.3: Sales of types of autoimmune brands, 2005-06
    • Figure 2.4: Competitive dynamics of the global autoimmune market by drug class, 2006
    • Figure 2.5: Competitive dynamics of the leading 10 brands in the global autoimmune market,2005-06
    • Figure 2.6: Competitive dynamics of the leading immunosuppressant treatments in the global autoimmune market, 2005-6
    • Figure 2.7: Competitive dynamics of the leading antirheumatic treatments in the global autoimmune market, 2005-6
    • Figure 2.8: Competitive dynamics of the leading NSAID treatments in the global autoimmune market, 2005-06
    • Figure 2.9: Competitive dynamics of the leading topical antirheumatic treatments in the global autoimmune market, 2005-06
    • Figure 2.10: Competitive dynamics of the leading COX-II treatments in the global autoimmune market, 2005-6
    • Figure 2.11: Competitive dynamics of the leading corticosteroid treatments in the globalautoimmune market, 2005-06
    • Figure 3.12: Prevailing R&D approaches, 2006
    • Figure 3.13: The autoimmune pipeline by indication and stage of development, 2006
    • Figure 3.14: Leading recently launched products and late-stage R&D compounds indicated for the treatment of autoimmune disorders, 2006
    • Figure 4.15: Competitive dynamics of the leading players in the global autoimmune market,
    • Figure 4.16: Amgen's auto-immune sales, 2006
    • Figure 4.17: J&J's autoimmune sales, 2006
    • Figure 4.18: Pfizer's autoimmune sales, 2006
    • Figure 4.19: Novartis' autoimmune sales by drug class, 2006
    • Figure 4.20: Abbott's autoimmune sales by drug class, 2006
    • Figure 4.21: Wyeth's autoimmune sales by drug class, 2006
    • Figure 4.22: Roche's autoimmune sales by drug class, 2006
    • Figure 4.23: Astellas' autoimmune salesby drug class, 2006
    • Figure 4.24: BI's autoimmune salesby drug class, 2006
    • Figure 4.25: Schering-Plough's autoimmune sales by drug class, 2006
  • List of Tables
    • Table 1.1: Estimated prevalence of autoimmune-related diseases in the seven major pharmaceutical markets, 2006
    • Table 1.2: Estimated prevalence of osteoarthritis across the seven major pharmaceutical markets,2006
    • Table 1.3: Estimated prevalence of rheumatoid arthritis across the seven major pharmaceutical markets, 2006
    • Table 1.4: Forecast prevalence of OA across the seven major markets,
    • Table 1.5: Forecast prevalence of RA across the seven major markets,
    • Table 1.6: Estimated prevalence of ankylosing spondylitis across the seven major pharmaceutical markets, 2006
    • Table 1.7: Estimated prevalence of psoriatic arthritis across the seven major pharmaceutical markets, 2006
    • Table 1.8: Forecast prevalence of ankylosing spondylitis across the seven major markets, 2006-12
    • Table 1.9: Forecast prevalence of psoriatic arthritis across the seven major markets, 2006-12
    • Table 1.10: Estimated prevalence of lupus across the seven major pharmaceutical markets, 2006
    • Table 1.11: Forecast prevalence of lupus across the seven major markets, 2006-12
    • Table 1.12: Estimated prevalence of psoriasis across seven major markets, 2006
    • Table 1.13: Forecast prevalence of psoriasis across the seven major markets, 2006-12
    • Table 1.14: Estimated prevalence of Crohn's disease in the seven major pharmaceutical markets,2006
    • Table 1.15: Forecast prevalence of Crohn's disease across the seven major markets, 2006-12
    • Table 2.16: Breakdown of the global autoimmune market by drug class, 2002-06
    • Table 2.17: Leading brands in the global autoimmune market, 2005-06
    • Table 2.18: Leading immunosuppressant brands in the global autoimmune market, 2005-06
    • Table 2.19: Immunosuppressive agents sales forecast, 2006-12
    • Table 2.20: Leading antirheumatic brands in the global autoimmune market, 2005-06
    • Table 2.21: Antirheumatics sales forecast, 2006-12
    • Table 2.22: Leading NSAID brands in the global autoimmune market, 2005-06
    • Table 2.23: NSAIDs sales forecast, 2006-12
    • Table 2.24: Leading topical antirheumatic brands in the global autoimmune market, 2005-06
    • Table 2.25: Topical antirheumatic sales forecast, 2006-12
    • Table 2.26: Leading COX-II brands in the global autoimmune market, 2005-06
    • Table 2.27: COX-II inhibitors sales forecast, 2006-12
    • Table 2.28: Leading corticosteroids brands in the global autoimmune market, 2005-06
    • Table 2.29: Corticosteroids sales forecast, 2006-12
    • Table 2.30: Therapeutic sales forecasts by drug class, 2006-112
    • Table 3.31: Autoimmune pipeline sales forecasts, 2006-12
    • Table 4.32: Leading players in the global autoimmune market, 2005-06
    • Table 4.33: Amgen's autoimmune product portfolio, 2004-05
    • Table 4.34: Amgen's autoimmune R&D product pipeline, 2006
    • Table 4.35: J&J's autoimmune product portfolio, 2005-06
    • Table 4.36: J&J's autoimmune R&D product pipeline, 2006
    • Table 4.37: Pfizer's autoimmune product portfolio, 2005-06
    • Table 4.38: Pfizer's auto immune R&D product pipeline, 2006
    • Table 4.39: Novartis' autoimmune product portfolio, 2005-06
    • Table 4.40: Novartis' autoimmune R&D product pipeline, 2006
    • Table 4.41: Abbott's autoimmune product portfolio, 2005-06
    • Table 4.42: Abbott's autoimmune R&D product pipeline, 2006
    • Table 4.43: Wyeth's autoimmune product portfolio, 2005-06
    • Table 4.44: Wyeth's autoimmune R&D product pipeline, 2006
    • Table 4.45: Roche's autoimmune product portfolio, 2005-06
    • Table 4.46: Roche's autoimmune R&D product pipeline, 2006
    • Table 4.47: Astellas' autoimmune product portfolio, 2005-06
    • Table 4.48: Astellas' autoimmune R&D product pipeline, 2006
    • Table 4.49: BI's autoimmune product portfolio, 2005-06
    • Table 4.50: BI's autoimmune R&D product pipeline, 2006
    • Table 4.51: Schering-Plough's autoimmune product portfolio, 2005-06
    • Table 4.52: Schering-Plough's autoimmune R&D product pipeline, 2006